The post analyses recent developments in patent and intellectual property, including AstraZeneca’s sale of rights to cancer drugs and South Korea’s new IP backed financing initiatives. It also covers IIT Delhi’s increased IP filings and international updates from Saudi Arabia.
Read more about AstraZeneca sells rights over two patented cancer drugs, South Korea introduces IP backed financing and moreTag: AstraZeneca
Lee Pharma v. AstraZeneca- An unfinished Patent Story
This post examines the Lee Pharma v. AstraZeneca case on compulsory licensing under Indian patent law. The Controller’s decision sheds light on the standards for proving public need, affordable pricing, and working of patents in India.
Read more about Lee Pharma v. AstraZeneca- An unfinished Patent StoryAstrazeneca to retain Sweetness of Onglyza
Astrazeneca has brought a patent infringement case against Aurobindo Pharma over an ANDA filing for Onglyza’s generic version in the US. The dispute centres on the alleged infringement of Saxagliptin hydrochloride patents before their expiry.
Read more about Astrazeneca to retain Sweetness of Onglyza